Introduction Astellas Pharma Inc. is a pharmaceutical company with a global presence. The company's core products include anticancer agents, treatments for overactive bladder, and immunosuppressants for organ transplantation. Astellas' competitiveness stems from its innovative R&D and extensive network, which includes cutting-edge technology gained through collaborations with academia, bio-ventures, and pharmaceutical companies worldwide. Astellas has implemented the "Focus Area Approach" as its R&D strategy, focusing on building sustainable and expandable drug discovery by selecting the best combination of biology, modality/technology, and disease. The company has identified four prioritized research areas: Blindness & Regeneration, Mitochondria Biology, Genetic Regulation, and Immuno-Oncology, named "Primary Focus" where it strategically expands its pipeline. Collaborations with academic labs and various pharmaceutical companies, including start-ups, are a key focus for Astellas. Dedicated teams have been assigned to maximize the value of these collaborations, including Astellas Innovation Management, Business Development, and Astellas Venture Management. |






